Genprex
Update in progressGNPX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Genprex is a clinical-stage gene therapy company focused on cancer and diabetes. Its oncology program uses the systemic, non-viral Oncoprex Delivery System to deliver gene-instructed therapies via lipid nanoparticles. Lead candidate Reqorsa Gene Therapy (quaratusugene ozeplasmid) targets NSCLC, SCLC, and mesothelioma, with FDA designations for three lung cancers and orphan status for SCLC. Its diabetes program uses AAV-delivered Pdx1 and MafA (GPX-002) to restore insulin production. Based in Austin, TX, since 2009, it collaborates with MD Anderson, UM Rogel Cancer Center, and others.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.13
- Governance
- 0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!